Differential Therapeutic Profile of Efruxifermin in the GAN DIO-MASH and CDAA-HFD Mouse Models of MASH
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX) is a long-acting FGF21 analogue currently inphase 3 clinical development for pre-cirrhotic…
A Multimodal Rat Brain Atlas and Whole-Brain Imaging Pipeline for Mapping Satiety Pathways and Anti-Obesity Drug Effects
Background & aim: Central regulation of appetite and satiety engages neuronal populations distributed across the brain. The identification of novel drug targets, development of anti-obesity therapeutics, and validation of their mode of action benefit from whole-brain imaging. Light-sheet fluorescence…
Nintedanib lacks efficacy in a spirometry-confirmed and bleomycin-induced mouse model of idiopathic pulmonary fibrosis
Abstract: Nintedanib, a multitargeted tyrosine kinase inhibitor, is approved for idiopathic pulmonary fibrosis (IPF) for its ability to slow lung function decline. This study systematically evaluated the effects of nintedanib across three independent treatment intervention studies in the single-dose bleomycin…
AI-driven whole-brain cellular profiling using 3D microscopy
Background & aim: Neurodegenerative diseases are characterized by complex, large-scale structural and cellular alterations across the brain. Understanding these changes requires comprehensive, whole-brain analysis at high spatial resolution. Three-dimensional light sheet fluorescence microscopy (3D LSFM) enables rapid imaging of intact…